Peregrion empowers drug innovators to accelerate clinical timelines.
We deliver definitive human ADME insights from Phase 1.
Traditionally, finding out exactly how a new drug asset transits and metabolizes inside the human body happens very late in the process. By the time human ADME is finally tested in late-stage human trials, millions of dollars have been spent, and years have passed, with the risk that drug developers will discover that unexpected human unique metabolites are formed.
Peregrion eliminates this systemic risk. We achieve this through specialized microtracer services. By applying 100 times less radiation than conventional methods, microtracer studies can be done as early as Phase 1. This results in early insights on how the human body absorbs, metabolizes and excretes the medicine. This provides pharma and biotech companies with the definitive, early-stage proof they need to protect their capital and refine continued development.
As a TNO spin-off rooted in 15+ years of research, Peregrion leverages proprietary Accelerator Mass Spectrometry (AMS) technology to enable ethical 14C-microtracer studies as early as Phase 1.
A foundation of scientific trust
Our capability is built on a strong scientific foundation. As a specialized spin-off from the renowned Dutch research organization TNO, Peregrion inherits more than a decade of pioneering research in Accelerator Mass Spectrometry (AMS) technology and trusted partnerships with global pharmaceutical leaders. Our operations are powered by a proprietary, automated auto-combustion AMS platform. This system delivers 500-fold greater sensitivity than conventional analytical methods by isolating and quantifying carbon-14 isotopes, yielding high-integrity data from microtracer doses. Operating from the heart of the European biotech corridor, our expert team translates this physical science into regulatory-compliant, scalable clinical execution.
